Tanguy Yann Lim-Seiwert MD Tanguy Seiwert, MD

Oncology•Baltimore, MD

Head & Neck Cancer, Thoracic Cancer

Johns Hopkins University

Join to View Full Profile

201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194

Summary

Dr. Tanguy Seiwert is an oncologist in Baltimore, MD. He received his medical degree from Johannes Gutenberg University of Mainz Faculty of Medicine and has been in practice 18 years. He specializes in head & neck cancer and thoracic cancer.

Education & Training

Johannes Gutenberg University of Mainz Faculty of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2019 - 2026
IL State Medical License 2003 - 2020
American Board of Internal Medicine Medical Oncology

Clinical Trials

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2013 May 01
Completed
Phase 1, Phase 2
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer Start of enrollment: 2018 Jun 01
Terminated
Phase 2
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Start of enrollment: 2017 May 10
Active, not recruiting
Phase 2
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Start of enrollment: 2017 Jun 27
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Lower survival for surgical treatment of human papillomavirus-related oropharynx cancer at community cancer centers.
Danielle R Trakimas, Wojciech K Mydlarz, Leila J Mady, Christine G Gourin, Wayne Koch
Journal of the National Cancer Institute. 2025-03-01
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
Stephanie L Alden, Soren Charmsaz, Howard L Li, Hua-Ling Tsai, Ludmila Danilova
Journal for Immunotherapy of Cancer. 2025-01-19
Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab.
Arun Khattri, Nizamuddin Sheikh, Nikhil Agrawal, Sandeep Kaushik, Sara Kochanny
Cancer Gene Therapy. 2024-10-01

Press Mentions

The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 26th, 2018
Reduced RT Feasible in Chemo-Sensitive HPV-Associated Head and Neck CancerFebruary 19th, 2018
Lower-Dose Radiation Therapy Effective and Safe for HPV-Related Head and Neck Cancer After Induction Chemotherapy, Trial FindsFebruary 13th, 2018
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member